gila monster glp 1 discovery We wouldn't have Ozempic without monsters — their hunger-regulating venom inspired weight-loss drugs Weight loss and diabetes drug

The hair growth cycle itself cannot be accelerated beyond biological limits

2026 American Peptides

With 23% of US households already including at least one GLP-1 user, spending on savory snacks, baked goods, and calorie-dense convenience food falling measurably, and JPMorgan projecting $30 to $55 billion in food and beverage revenue reduction by 2030 to 2034, the portfolio implications are real and unevenly distributed

IQVIA LAAD Pharmacy Claims Data Indication Expansion and Unique Payer Responses Despite restrictions on anti-obesity medications in Medicare, Wegovy and Zepbound have found ways to improve their coverage

3:00 - Katie as the Bridge Between Academia and Industry Ben acknowledges Katie's unique ability to bridge the gap between academic standards and practical industry applications